LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 88

Suchoptionen

  1. Artikel ; Online: Daily second-generation INSTIs and short-course TPT: What more do we need to know?

    Chamie, Gabriel / Luetkemeyer, Anne F

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2023  

    Sprache Englisch
    Erscheinungsdatum 2023-12-05
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciad726
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Postexposure Doxycycline for Sexually Transmitted Infections. Reply.

    Luetkemeyer, Anne F / Cannon, Chase / Celum, Connie

    The New England journal of medicine

    2023  Band 389, Heft 3, Seite(n) 286–287

    Mesh-Begriff(e) Humans ; Doxycycline/therapeutic use ; Sexually Transmitted Diseases/drug therapy ; Sexually Transmitted Diseases/prevention & control ; Anti-Bacterial Agents/therapeutic use
    Chemische Substanzen Doxycycline (N12000U13O) ; Anti-Bacterial Agents
    Sprache Englisch
    Erscheinungsdatum 2023-07-19
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2306480
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Risk of antimicrobial resistance with doxy-PEP is real, as is the need for its well-Informed implementation.

    Hazra, Aniruddha / Celum, Connie / Luetkemeyer, Anne F / Molina, Jean-Michel / Klausner, Jeffrey D

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-03-19
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciae152
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How?

    Matthay, Michael A / Luetkemeyer, Anne F

    JAMA

    2021  Band 326, Heft 6, Seite(n) 483–485

    Mesh-Begriff(e) COVID-19 ; Humans ; Immunologic Factors ; Interleukin-6 ; Receptors, Interleukin-6 ; SARS-CoV-2
    Chemische Substanzen Immunologic Factors ; Interleukin-6 ; Receptors, Interleukin-6
    Sprache Englisch
    Erscheinungsdatum 2021-07-14
    Erscheinungsland United States
    Dokumenttyp Editorial ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2021.11121
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Doxycycline for Sexually Transmitted Infection Prevention: Evolving Evidence and Implementation Perspectives.

    Celum, Connie / Luetkemeyer, Anne F

    Sexually transmitted diseases

    2021  Band 48, Heft 9, Seite(n) 620–621

    Mesh-Begriff(e) Chlamydia Infections ; Doxycycline/therapeutic use ; Humans ; Sexually Transmitted Diseases/epidemiology ; Sexually Transmitted Diseases/prevention & control
    Chemische Substanzen Doxycycline (N12000U13O)
    Sprache Englisch
    Erscheinungsdatum 2021-05-19
    Erscheinungsland United States
    Dokumenttyp Editorial ; Comment
    ZDB-ID 435191-5
    ISSN 1537-4521 ; 0148-5717
    ISSN (online) 1537-4521
    ISSN 0148-5717
    DOI 10.1097/OLQ.0000000000001501
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: CROI 2021: Viral Hepatitis and Other Forms of Liver Injury Impacting People with HIV.

    Luetkemeyer, Anne F / Wyles, David L

    Topics in antiviral medicine

    2021  Band 29, Heft 3, Seite(n) 379–385

    Abstract: At the 2021 Conference on Retroviruses and Opportunistic Infections, there was a focus on progress toward hepatitis C virus (HCV) microelimination in geographic regions and targeted populations. HCV elimination is facilitated by well-tolerated, highly ... ...

    Abstract At the 2021 Conference on Retroviruses and Opportunistic Infections, there was a focus on progress toward hepatitis C virus (HCV) microelimination in geographic regions and targeted populations. HCV elimination is facilitated by well-tolerated, highly effective HCV treatment that requires essentially no on-treatment monitoring in most patients, as highlighted by the MINMON (Minimal Monitoring Study or A5360) study, and that should be increasingly available to children with new data supporting feasible treatment in younger patients. Challenges to HCV elimination include HCV reinfection via sexual exposure in men who have sex with men (MSM) and continued barriers to diagnosis and access to HCV treatment. Hepatitis B virus (HBV) suppression may take years in HIV/HBV-coinfected patients. This may have important consequences as the risk for hepatocellular carcinoma was associated in a dose-dependent manner with HBV viral load and was lowest in those with sustained undetectable HBV, highlighting the need for HBV DNA monitoring during therapy. Public health programs should prioritize improving hepatitis A and hepatitis B vaccination in at-risk populations, including people with HIV, as vaccinations rates for these preventable diseases continue to be suboptimal in many settings. Fatty liver disease, heavy alcohol use, antiretroviral therapy, and COVID-19 infection were also examined as drivers of hepatic disease in HIV infection.
    Mesh-Begriff(e) Biomedical Research ; Congresses as Topic ; HIV Infections/complications ; Hepatitis A/complications ; Hepatitis B/complications ; Hepatitis C/complications ; Hepatitis, Viral, Human/complications ; Homosexuality, Male ; Humans ; Liver/injuries ; Male
    Sprache Englisch
    Erscheinungsdatum 2021-08-02
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2656632-1
    ISSN 2161-5853 ; 2161-5853
    ISSN (online) 2161-5853
    ISSN 2161-5853
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: CROI 2019: highlights of viral hepatitis.

    Luetkemeyer, Anne F / Wyles, David L

    Topics in antiviral medicine

    2019  Band 27, Heft 1, Seite(n) 41–49

    Abstract: At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Many interventions showed promising improvements in ... ...

    Abstract At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Many interventions showed promising improvements in diagnosis and linkage to care. Settings with robust access to direct-acting antivirals (DAAs) continue to demonstrate the role of HCV treatment as prevention. However, substantial barriers to accessing curative therapy remain. Reinfection after treatment presents an important barrier to elimination, particularly in some populations of men who have sex with men (MSM). MSM without HIV infection are at an elevated risk for sexual acquisition of HCV, and several studies reported HCV rates that were as high as those seen in MSM living with HIV. There was also a focus on HCV and HBV in pregnant women. Rates of HCV infection in women of child-bearing potential have increased, making prenatal diagnosis a priority. In the first study of HCV treatment during pregnancy, sofosbuvir/ledipasvir started at 28 weeks of gestation led to cure in 8 pregnant women. Hepatitis B virus (HBV)-active antiretrovirals are generally effective in suppressing HBV but have low rates of surface antigen loss despite long term treatment. Initial results from novel laboratory assessments of intrahepatic HBV viral infection events were presented, hopefully paving the way for more effective HBV treatment strategies to control and potentially cure HBV.
    Mesh-Begriff(e) Antiviral Agents/therapeutic use ; HIV Infections/complications ; HIV Infections/drug therapy ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Humans
    Chemische Substanzen Antiviral Agents
    Sprache Englisch
    Erscheinungsdatum 2019-05-25
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2656632-1
    ISSN 2161-5853 ; 2161-5861
    ISSN (online) 2161-5853
    ISSN 2161-5861
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: CROI 2018: Highlights of Viral Hepatitis.

    Luetkemeyer, Anne F / Wyles, David L

    Topics in antiviral medicine

    2018  Band 26, Heft 1, Seite(n) 30–38

    Abstract: At the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Several countries and cohorts have demonstrated the ... ...

    Abstract At the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Several countries and cohorts have demonstrated the remarkable impact that universal HCV testing and unrestricted access to hepatitis C treatment can have on markedly reducing incident HCV infections and HCV infection prevalence, including in people who inject drugs and HIV/HCV-coinfected populations. However, in many settings, substantial barriers to widespread HCV treatment remain, including undiagnosed HCV infection, particularly in populations outside the standard "baby boomer" birth cohort (ie, born 1945-1965); restricted access to hepatitis C treatment in those with known HCV infection; reinfection with HCV; and migration of HCV-infected populations. Many innovative programs have successfully implemented HCV testing and treatment outside of traditional care settings, expanding access for harder-to-reach populations, which will be crucial to successful elimination efforts. Outbreaks of hepatitis A virus (HAV) infection continue to occur in among men who have sex with men and homeless populations in the United States, Europe, and Southeast Asia, highlighting the need for improved HAV vaccination programs for populations at risk.
    Mesh-Begriff(e) Antiviral Agents/therapeutic use ; Coinfection ; Congresses as Topic/trends ; Global Health ; HIV Infections/drug therapy ; Hepatitis C/drug therapy ; Hepatitis C/epidemiology ; Hepatitis C/prevention & control ; Humans ; Mass Screening/methods ; Prevalence
    Chemische Substanzen Antiviral Agents
    Sprache Englisch
    Erscheinungsdatum 2018-05-03
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2656632-1
    ISSN 2161-5853 ; 2161-5861
    ISSN (online) 2161-5853
    ISSN 2161-5861
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections.

    Hazra, Aniruddha / McNulty, Moira C / Pyra, Maria / Pagkas-Bather, Jade / Gutierrez, Jose I / Pickett, Jim / Stewart, Jenell / Bolan, Robert K / Molina, Jean-Michel / Celum, Connie / Luetkemeyer, Anne F / Klausner, Jeffrey D

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2024  

    Abstract: Over the past two decades, cases of sexually transmitted infections (STIs) due to syphilis, gonorrhea, and chlamydia have been rising in the United States, disproportionately among gay, bisexual, and other men who have sex with men (MSM), as well as ... ...

    Abstract Over the past two decades, cases of sexually transmitted infections (STIs) due to syphilis, gonorrhea, and chlamydia have been rising in the United States, disproportionately among gay, bisexual, and other men who have sex with men (MSM), as well as racial and ethnic minorities of all genders. In this review, we address updates about the evidence on doxycycline post-exposure prophylaxis (doxy-PEP) for prevention of bacterial STIs, including efficacy, safety, antimicrobial resistance (AMR), acceptability, modeling population impact, and evolving guidelines for use. Equitable implementation of doxy-PEP will require evaluation of who is offered and initiates it, understanding patterns of use and longer-term STI incidence and AMR, provider training, and tailored community education.
    Sprache Englisch
    Erscheinungsdatum 2024-02-09
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciae062
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.

    Wyles, David L / Luetkemeyer, Anne F

    Topics in antiviral medicine

    2017  Band 25, Heft 3, Seite(n) 103–109

    Abstract: Viral resistance to direct-acting antiviral drugs may impact their effectiveness during treatment of hepatitis C virus (HCV) infection. Most data on HCV drug resistance concern genotypes 1 and 3. The clinical impact of resistance to HCV nonstructural ... ...

    Abstract Viral resistance to direct-acting antiviral drugs may impact their effectiveness during treatment of hepatitis C virus (HCV) infection. Most data on HCV drug resistance concern genotypes 1 and 3. The clinical impact of resistance to HCV nonstructural protein 5A (NS5A) inhibitors and a practical approach to indications and methods for resistance testing are discussed.
    Mesh-Begriff(e) Antiviral Agents ; Drug Resistance, Viral ; HIV Infections ; Hepacivirus ; Humans ; Viral Nonstructural Proteins
    Chemische Substanzen Antiviral Agents ; Viral Nonstructural Proteins
    Sprache Englisch
    Erscheinungsdatum 2017-08-11
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2656632-1
    ISSN 2161-5853 ; 2161-5861
    ISSN (online) 2161-5853
    ISSN 2161-5861
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang